GBA1 and Parkinson disease: Insight into the effects of different GBA variants on GCase activity in the brain can be important for patient selection and therapeutic efficacy for novel therapies that aim to increase GCase enzyme activity as disease-modifying therapy in PD/DLB, for instance using small molecule non-inhibitory chaperones [48].